CDEK
← All organizations

Sumitomo Dainippon

For profitContributed to NMEWebsite ↗

Also known as: Dainippon Sumitomo | Dainippon Sumitomo Pharma America | Dainippon Sumitomo Pharma Co., Ltd. | Dainippon Sumitomo Pharma Europe LTd. | Sumitomo Dainippon Pharma | Sumitomo Dainippon Pharma Co., Ltd. | Sumitomo Dainippon Pharma Oncology | Sumitomo Dainippon Pharma Oncology, Inc | Sumitomo Dainippoon Pharma | Sumitomo Pharma America, Inc. | Valent Technologies, Inc.

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 3

First clinical trial

Oct 1, 2004

First marketed drug

Oct 28, 2010

First NDA

Oct 28, 2010

Last known activity

Oct 23, 2025

Timeline

1990s

  1. Oct 1, 1995

    Sumitomo Dainippon— Founded

2000s

  1. Jan 1, 2005

    Dainippon Seiyaku— Acquired

  2. Jan 1, 2005

    Sumitomo— Acquired

  3. Dec 1, 2009

    Sunovion— Acquired

2010s

  1. Jan 1, 2012

    Boston Biomedical— Acquired

  2. Jun 1, 2017

    Tolero Pharmaceuticals— Acquired

  3. Sep 6, 2019

    Altavant— Acquired

  4. Sep 6, 2019

    Enzyvant Therapeutics GmbHEnzyvant Therapeutics GmbH— Acquired

  5. Sep 6, 2019

    Myovant Sciences GmbH— Acquired

  6. Sep 6, 2019

    Urovant Sciences Ltd.Urovant Sciences Ltd.— Acquired

2020s

  1. Dec 18, 2020

    relugolix— NDA Organization

  2. Dec 18, 2020

    relugolix— NDA Secondary Org

Drugs by trial phase (149 distinct, 358 trials)

Indications

Approved for

Studied for

Marketed drugs (10)

Subsidiaries (9 direct, 16 total across the full acquisition tree)

Recent trials (50)

Details

Founded
Osaka, JP Oct 1, 1995
First NDA
Oct 28, 2010
Last known activity
Oct 23, 2025

Designations held

  • Orphan drug
  • Priority review
  • Breakthrough therapy